Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study

TY - JOUR

T1 - Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy

T2 - a pilot study

AU - Quist, Morten

AU - Rørth, Mikael

AU - Langer, Seppo

AU - Jones, Lee W

AU - Laursen, Jørgen H

AU - Pappot, Helle

AU - Christensen, Karl Bang

AU - Adamsen, Lis

N1 - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

PY - 2012/2

Y1 - 2012/2

N2 - Aim: To investigate the safety and feasibility of a six-week supervised structured exercise and relaxation training programme on estimated peak oxygen consumption, muscle strength and health related quality of life (HRHRQOL) in patients with inoperable lung cancer, undergoing chemotherapy. Methods: A prospective, single-arm intervention study of supervised, hospital based muscle and cardiovascular group training and individual home-based training. Peak oxygen consumption (VO2peak) was assessed using an incremental exercise test. Muscle strength was measured with one repetition maximum test (1RM). HRQOL was assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale. Results: Twenty-five patients with non-small cell cancer (NSCLC) stage III-IV and four patients with extensive disease small cell lung cancer (SCLC-ED) were recruited. Six patients (20.7%) dropped out leaving 23 patients for analysis. Exercise adherence in the group training was 73.0% and 8.7% in the home-based training. There were improvements in estimated VO2peak and six-minute walk distance (6 MWD) as well as increased muscle strength measurements (p<0.05). There was significant improvement in the "emotional well-being" parameter (FACT-L) while there were no significant changes in HRQOL. Conclusion: Exercise training produces significant improvements in physiological indices and emotional HRQOL and is safe and feasible in patients with advanced stage lung cancer, undergoing chemotherapy. No analysis on home-based training was done because of low adherence.

AB - Aim: To investigate the safety and feasibility of a six-week supervised structured exercise and relaxation training programme on estimated peak oxygen consumption, muscle strength and health related quality of life (HRHRQOL) in patients with inoperable lung cancer, undergoing chemotherapy. Methods: A prospective, single-arm intervention study of supervised, hospital based muscle and cardiovascular group training and individual home-based training. Peak oxygen consumption (VO2peak) was assessed using an incremental exercise test. Muscle strength was measured with one repetition maximum test (1RM). HRQOL was assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale. Results: Twenty-five patients with non-small cell cancer (NSCLC) stage III-IV and four patients with extensive disease small cell lung cancer (SCLC-ED) were recruited. Six patients (20.7%) dropped out leaving 23 patients for analysis. Exercise adherence in the group training was 73.0% and 8.7% in the home-based training. There were improvements in estimated VO2peak and six-minute walk distance (6 MWD) as well as increased muscle strength measurements (p<0.05). There was significant improvement in the "emotional well-being" parameter (FACT-L) while there were no significant changes in HRQOL. Conclusion: Exercise training produces significant improvements in physiological indices and emotional HRQOL and is safe and feasible in patients with advanced stage lung cancer, undergoing chemotherapy. No analysis on home-based training was done because of low adherence.

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Non-Small-Cell Lung

KW - Exercise Therapy

KW - Female

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Muscle Strength

KW - Oxygen Consumption

KW - Patient Compliance

KW - Pilot Projects

KW - Prospective Studies

KW - Quality of Life

U2 - 10.1016/j.lungcan.2011.07.006

DO - 10.1016/j.lungcan.2011.07.006

M3 - Journal article

C2 - 21816503

SN - 0169-5002

VL - 75

SP - 203

EP - 208

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -